Phase II, Open Label, Non-randomized, Trial of BKM120 as Palliative Treatment for Metastatic or Locally Advanced Cervical Cancer After Failure to Platinum Based Regimen

Trial Profile

Phase II, Open Label, Non-randomized, Trial of BKM120 as Palliative Treatment for Metastatic or Locally Advanced Cervical Cancer After Failure to Platinum Based Regimen

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Buparlisib (Primary)
  • Indications Cervical cancer
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 03 Feb 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
    • 12 Jan 2016 Planned number of patients changed from 27 to 29 as reported by ClinicalTrials.gov.
    • 12 Jan 2016 Planned initiation date changed from 1 Nov 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top